Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stock Holdings Trimmed by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. decreased its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 35.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 32,003 shares of the company's stock after selling 17,724 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Genmab A/S were worth $630,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Marotta Asset Management lifted its position in Genmab A/S by 5.8% during the 1st quarter. Marotta Asset Management now owns 13,532 shares of the company's stock worth $265,000 after acquiring an additional 739 shares during the period. EverSource Wealth Advisors LLC increased its stake in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC increased its position in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after buying an additional 950 shares in the last quarter. Laird Norton Wetherby Wealth Management LLC increased its position in Genmab A/S by 17.3% during the fourth quarter. Laird Norton Wetherby Wealth Management LLC now owns 13,711 shares of the company's stock worth $286,000 after buying an additional 2,023 shares in the last quarter. Finally, NewEdge Advisors LLC increased its position in Genmab A/S by 12.7% during the fourth quarter. NewEdge Advisors LLC now owns 19,304 shares of the company's stock worth $403,000 after buying an additional 2,171 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on GMAB shares. HC Wainwright reissued a "buy" rating and set a $37.00 price target (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. Wall Street Zen cut Genmab A/S from a "buy" rating to a "hold" rating in a report on Saturday, June 14th. Finally, Truist Financial raised their price objective on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $37.80.

Genmab A/S Stock Performance

Genmab A/S stock traded up $0.33 during midday trading on Wednesday, reaching $21.58. The stock had a trading volume of 1,243,702 shares, compared to its average volume of 1,244,145. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $28.56. The stock has a market capitalization of $13.84 billion, a PE ratio of 12.26, a price-to-earnings-growth ratio of 6.73 and a beta of 0.94. The stock's 50-day simple moving average is $21.02 and its 200 day simple moving average is $20.73.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. The company had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. Equities analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.